A phase II study of gemcitabine, carboplatin and PS-341 (NSC-681239) [bortezomib] in the first-line treatment of advanced non-small cell lung cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2013
At a glance
- Drugs Bortezomib (Primary) ; Carboplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 23 Jul 2012 Actual end date (1 Aug 2009) added as reported by ClinicalTrials.gov.
- 02 Oct 2005 New trial record.